하이드로코돈
하이드로코돈 · Hydrocodon · Dihydrocodeinone · Dico · 50-100g · Bekadid · Dicodid · Codinovo
식별자 및 물리적 특성
| CAS No. | 125-29-1 |
|---|---|
| 분자식 | C18H21NO3 |
| 평균 분자량 | 299.4 g/mol |
| 단동위원소 질량 | 299.15214353 g/mol |
| SMILES | COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314 |
| InChIKey | LLPOLZWFYMWNKH-CMKMFDCUSA-N |
| PubChem CID | 5284569 |
| ChEMBL | CHEMBL1457 |
| ChEBI | CHEBI:5779 |
| EC No. | 204-733-9 |
| DTXSID | DTXSID8023131 |
| 현지명 | 하이드로코돈 |
화학 및 물리적 성질
| XLogP | 2.2 |
|---|---|
| 극성 표면적 | 38.8 |
| 수소 결합 공여자 수 | 0 |
| 수소 결합 수용자 수 | 4 |
| 회전 가능 결합 수 | 1 |
| 무거운 원자 수 | 22 |
| 형식 전하 | 0 |
| 복잡도 | 509 |
| 물질 분류 | Pharmaceutical |
| 의약품 | DEA NFLIS-Drug Category -> Narcotic AnalgesicsDEA Schedule II Controlled SubstancePharmaceuticals -> Synthetic Cannabinoids or Psychoactive CompoundsPharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 1.2 |
| Color/Form | Prisms from alcohol |
| 용해도 | Soluble in acetone, ethyl acetate, chloroformSoluble in ethanol7.97e-01 g/L클로로포름(약간 용해됨), 에틸아세테이트(약간 용해됨), 메탄올(약간 용해됨) |
| 인화점 | 9.7 °C (49.5 °F) - closed cup9℃ |
| Human Drugs | Breast FeedingLactationMilk, HumanAnalgesics, OpioidNarcoticsAntitussive AgentsFDA approved drugs -> Active ingredientPharmaceuticals |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Decomposition | When heated to decomposition it emits toxic fumes of /nitrogen oxide/. |
| 녹는점 | 198 °CMP: 219-220 °C /Hydrocodone hydriodide/MP: 250-225 °C /Hydrocodone methiodide/194-197°C |
| Optical Rotation | Specific optical rotation = -203 deg at 25 °C/D ( c = 0.41 in CHCL3) |
| Physical Description | Solid |
| 끓는 점 | 440.69°C (rough estimate) |
| 밀도 | 1.1613 (rough estimate) |
| 굴절률 | 1.5500 (estimate) |
| 저장 조건 | Controlled Substance, -20°C Freezer |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | pKa 6.61(50% aq EtOH) (Uncertain) |
| 색상 | 에탄올로부터 결정화하여 얻은 각형 결정 |
| 주요 응용 | 제약 |
| EPA | Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.)- (125-29-1) |
화학적 성질
Beige Solid
안전 및 규제
| GHS 분류 | DangerH302 (97.7%): Harmful if swallowed [Warning Acute toxicity, oral]P233, P260, P261, P264, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P321, P330, P333+P317, P342+P316, P362+P364, P391, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 43 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.H225: Highly Flammable liquid and vapor [Danger Flammable liquids] |
|---|---|
| 규제 정보 | DEA schedule II controlled substance |
| FDA 요건 | Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following. Hydrocodone (DEA Code Number: 9193) is included on this list.The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including hydrocodone bitartrate approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Hydrocodone bitartrate/The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including hydrocodone polistirex approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Hydrocodone polistirex/ |
| Hazard Classes and Categories | Acute Tox. 4 (97.7%) |
| Hazardous Reactivities and Incompatibilities | Incompatible materials: Acids, Oxidizing agents, Alkali metals, Strong oxidizing agents, Strong acids, Acid chlorides, Acid anhydrides, Reducing agents, Strong reducing agents, Phosphorus halides |
용도
용도
Hydrocodone is a powerful anticough drug that is widely used for suppressing the cough reflex. It is widely used in effective commercial anticough drugs in combination with guaiphenesin (entuss), with homatropine (hycodan), with phenylpropanolamine (hycomine), phenyltoloxamine (tussionex), and pseudoephedrine and guaiphenesin (tussened).
일반 설명
Hydrocodone is the 3 methoxy version of hydromorphone.The loss of the 3-OH group yields a compound that is approximately4 to 5 times less potent than hydromorphone, thusabout equal to morphine. Unlike codeine, the agonist activityof hydrocodone does not require 3-O-demethylation, althoughit does occur via CYP2D6 representing 4.6% of totalclearance. The protected 3-position has better brain penetration,and the 7,8-dihydro-6-keto C ring contributes to the increasedbinding of the compound to the μ-receptor.There are no pure hydrocodone products available on theU.S. market. All FDA-approved products containing hydrocodoneare combination products. Like codeine, hydrocodoneis marketed as an antitussive agent. It is availablecombined with the anticholinergic agent homatropineas a syrup and a tablet. The addition of the anticholinergicagent is to discourage abuse. It is also available in a delayedrelease suspension form (Tussionex). This formulation usesa sulfonated styrene divinylbenzene copolymer complexedwith hydromorphone and chlorpheniramine that acts as acation-exchange resin slowly releasing the drugs over a 12-hour period. Hydrocodone is also marketed in combinationwith acetaminophen (Vicodin, Lortab) or aspirin (LortabASA) for the treatment of pain. The dose of acetaminophenconsumed by the patient must be closely monitored, andprescriptions that allow for greater than 4 grams of acetaminophenper 24-hour period should not be dispensed.